# David G. Standaert

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-g-standaert/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,096 |
| Field | Parkinson's Disease Mechanisms and Treatments |
| h-index | 100 |
| i10-index | 262 |
| Last Known Institution | University of Alabama at Birmingham |
| OpenAlex ID | https://openalex.org/A5000374325 |
| ORCID iD | https://orcid.org/0000-0003-2921-8348 |
| Works | 440 |

## Researcher papers

- [The Parkinson Progression Marker Initiative (PPMI)](https://scholariq.org/papers/the-parkinson-progression-marker-initiative-ppmi/)
- [Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy](https://scholariq.org/papers/past-present-and-future-of-parkinson-s-disease-a-special-essay-on-the-200th/)
- [Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study](https://scholariq.org/papers/continuous-intrajejunal-infusion-of-levodopa-carbidopa-intestinal-gel-for/)
- [Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications](https://scholariq.org/papers/clinical-development-of-a-poly-2-oxazoline-poz-polymer-therapeutic-for-the/)
- [Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study](https://scholariq.org/papers/identification-of-genetic-risk-loci-and-causal-insights-associated-with/)
- [Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls](https://scholariq.org/papers/longitudinal-csf-biomarkers-in-patients-with-early-parkinson-disease-and-healthy/)
- [Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study](https://scholariq.org/papers/clinical-and-dopamine-transporter-imaging-characteristics-of-non-manifest-lrrk2/)

## Researcher topics

- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)
- [Neurological disorders and treatments](https://scholariq.org/topics/neurological-disorders-and-treatments/)
- [Neuroscience and Neuropharmacology Research](https://scholariq.org/topics/neuroscience-and-neuropharmacology-research/)
- [Genetic Neurodegenerative Diseases](https://scholariq.org/topics/genetic-neurodegenerative-diseases/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)

## Researcher university

- [University of Alabama at Birmingham](https://scholariq.org/institutions/university-of-alabama-at-birmingham/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.